Searched for
BIOPHARMACEUTICALS
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- Symbiotec Pharmalab shares list at 1% discount to IPO priceThe Symbiotec Pharmalab IPO plans to channel Rs 112.50 crore towards the prepayment and/or repayment, fully or partially, of select outstan...
- Not an animal, but one popular fruit shares 60% of human genes. Genetic expert says it’s not shocking: ‘There’s a lot of things we do the same way…'Who doesn’t like to munch on a banana or two during the summer? Although a guilty pleasure for those with high blood sugar levels, it remai...
- Symbiotec Pharmalab IPO Day 4: GMP at 29%, subscription reaches 5.31xSymbiotec Pharmalab's IPO saw strong investor demand, closing oversubscribed 71.26 times. The company aimed to raise Rs 1,757 crore through...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the possibility of hostilities resuming in the Gulf region, focus on risk management in the market. Why? Because fresh hostilities wi...
- Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?Symbiotec Pharmalab's IPO saw robust investor demand, with the issue subscribed 1.85 times. The company aims to raise Rs 1,757 crore throug...
- Global Market: China, Hong Kong stocks rise as AI rebound boosts investor sentimentOn Wednesday, stocks in China and Hong Kong surged, reflecting a favourable global market environment. Technology and artificial intelligen...
- Symbiotec Pharmalab’s Rs 1,757 crore IPO opens with GMP hinting at 41% upside. Should you bid?Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market pr...
- Mankind Pharma inks in-licensing pact with China's Chongqing Chenan BiopharmaceuticalMankind Pharma has secured an exclusive agreement with Chongqing Chenan Biopharmaceutical. This partnership focuses on commercialising two ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- Symbiotec Pharmalab sets price band for Rs 1,757 crore IPO, to open on August 24Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 1...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Emcure Pharma net profit up 36% at Rs 292 croreEmcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivi...
- Emcure Pharma Q1 profit jumps 36%, revenue rises 23%; appoints Samit Mehta as COO"We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- Indian economy to hit USD 5-trillion mark in FY29 as per IMF: FMIndia's economic landscape is on a promising trajectory, aiming to exceed five trillion dollars by the fiscal year twenty twenty-nine. To a...
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technologyThe ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...
Load More
